"Vancomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
| Descriptor ID |
D014640
|
| MeSH Number(s) |
D09.400.420.925 D12.644.233.925
|
| Concept/Terms |
Vancocin- Vancocin
- Vancocin HCl
- Vancomycin Lilly
- Vancocine
|
Below are MeSH descriptors whose meaning is more general than "Vancomycin".
Below are MeSH descriptors whose meaning is more specific than "Vancomycin".
This graph shows the total number of publications written about "Vancomycin" by people in this website by year, and whether "Vancomycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 3 | 4 |
| 2008 | 2 | 1 | 3 |
| 2009 | 4 | 0 | 4 |
| 2011 | 2 | 4 | 6 |
| 2012 | 2 | 6 | 8 |
| 2013 | 6 | 1 | 7 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 5 | 7 |
| 2017 | 4 | 7 | 11 |
| 2018 | 6 | 2 | 8 |
| 2019 | 4 | 2 | 6 |
| 2020 | 5 | 3 | 8 |
| 2021 | 1 | 2 | 3 |
| 2022 | 3 | 6 | 9 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 2 | 6 |
| 2025 | 6 | 4 | 10 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vancomycin" by people in Profiles.
-
Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward. Expert Rev Gastroenterol Hepatol. 2026 Mar; 20(3):233-246.
-
A Randomized Phase 1 Study Investigating Gut Microbiome Changes With Moxifloxacin vs Oral Vancomycin: Implications for Clostridioides difficile Risk. J Infect Dis. 2025 Dec 20; 232(6):1446-1456.
-
A multi-center collaborative highlights the differences in nephrotoxic medication exposure and associated AKI in pediatric bone marrow transplant, oncology, and pulmonary service lines. Pediatr Nephrol. 2026 Mar; 41(3):865-872.
-
Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study. Ultrastruct Pathol. 2025; 49(5):414-420.
-
Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
-
Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrob Agents Chemother. 2025 08 06; 69(8):e0028725.
-
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study. Lancet Microbe. 2025 Aug; 6(8):101126.
-
The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice. Antimicrob Agents Chemother. 2025 04 02; 69(4):e0160424.
-
Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia. BMC Infect Dis. 2025 Feb 18; 25(1):231.
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0125124.